Feature | September 15, 2009

Fluid Monitoring Predicted Three Times More Future Heart Failure Events Than Weight Monitoring Alone

September 15, 2009 – Fluid monitoring with OptiVol Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released yesterday from the FAST (Fluid Accumulation Status Trial) clinical trial.

Results showed that Medtronic Inc. OptiVol Fluid Status Monitoring, which measures changes in fluid build up in the chest cavity, predicted 76 percent of future heart failure events as compared to only 23 percent detected by weight monitoring alone. Medtronic said the results showed OptiVol was three times more sensitive. FAST findings were presented as a late breaking clinical trial during the 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Boston.

“This data shows that OptiVol Fluid Status Monitoring is a more accurate predictor of heart failure events than weight monitoring alone,” said William T. Abraham, M.D., professor of medicine and physiology, at Ohio State University and FAST principal investigator. “Instead of relying on patients with implantable heart devices to weigh themselves daily, the standard of care should include the use of implantable fluid status monitoring technology to identify worsening heart failure before symptoms worsen and lead to hospitalization.”

Key findings from FAST include:

• OptiVol accurately predicted 48 of 65 heart failure events in 31 patients, which corresponds to a per patient adjusted sensitivity (some patients had more than one heart failure event) of 76 percent, whereas weight monitoring detected 13 heart failure events for a per patient adjusted sensitivity of 23 percent.

• Forty heart failure events were predicted using OptiVol, but were not detected by weight monitoring. Conversely, weight monitoring identified only five events undetected by OptiVol. Eight events were detected by both fluid and weight monitoring.

• Fluid monitoring had an unexplained detection rate of 1.9 events per patient per year as compared with 4.3 events per patient per year with weight monitoring.

• OptiVol data was available for nearly every day of follow-up on all patients in the trial, whereas daily weight data was not provided by patients for 24 percent of the follow up period.

FAST is an international, prospective, double-blinded study involving 156 implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) patients followed for an average of 18 months at 18 centers in the United States, Canada and Hong Kong. Patients with an OptiVol fluid index crossing above 60 ohm days (units used to measure fluid index) were compared to acute weight increases of three pounds overnight or five pounds in three days. Heart failure events are defined as hospitalizations, emergency room visits, urgent care or unscheduled office visits. Heart failure events detected in this study were within 30 days of a fluid index threshold crossing or an acute weight gain. Unexplained detections were threshold crossings or acute weight gains not associated with a heart failure event.

The OptiVol Fluid Status Monitoring is available only on Medtronic CRT-Ds and ICDs, and has been available since FDA approval in 2004. It uses low-level electrical pulses that travel across the thoracic cavity (the chest area encompassing the lungs and heart) to measure the level of resistance, indicating fluid in the chest – a common sign of heart failure. Since normal fluid levels vary from patient to patient, and fluid accumulation can be either slow or rapid, OptiVol’s ability to measure fluid status trends over time can provide important insights that are used in conjunction with ongoing monitoring of other patient signs and symptoms. As of Jan. 1, 2009, the U.S. Centers for Medicare and Medicaid Services (CMS) began reimbursing physicians for their time spent monitoring heart failure patients using fluid trend data obtained from Medtronic implantable cardiac devices via a Medtronic CareLink Network remote transmission.

For more information: www.medtronic.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init